recombinant dna codon-optimized nme2cas9 Search Results


90
GenScript corporation codon-optimized nme2cas9
(A) Unrooted phylogenetic tree of meningococcal Cas9 orthologs. Groups 1 (blue), 2 (orange), and 3 (green) have PIDs with >98%, ~52%, and ~86% identity to Nme1Cas9, respectively. Three representative Cas9 orthologs (one from each group) (Nme1Cas9, <t>Nme2Cas9</t> and Nme3Cas9) are indicated.
Codon Optimized Nme2cas9, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+dna+codon-optimized+nme2cas9/recombinant+dna+codon+optimized+nme2cas9/pmc06386616-63-0-3
Average 90 stars, based on 1 article reviews
codon-optimized nme2cas9 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Unrooted phylogenetic tree of meningococcal Cas9 orthologs. Groups 1 (blue), 2 (orange), and 3 (green) have PIDs with >98%, ~52%, and ~86% identity to Nme1Cas9, respectively. Three representative Cas9 orthologs (one from each group) (Nme1Cas9, Nme2Cas9 and Nme3Cas9) are indicated.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) Unrooted phylogenetic tree of meningococcal Cas9 orthologs. Groups 1 (blue), 2 (orange), and 3 (green) have PIDs with >98%, ~52%, and ~86% identity to Nme1Cas9, respectively. Three representative Cas9 orthologs (one from each group) (Nme1Cas9, Nme2Cas9 and Nme3Cas9) are indicated.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques:

(A) Nme2Cas9 genome editing of endogenous human sites in HEK293T cells following transient transfection of Nme2Cas9- and sgRNA-expressing plasmids. 40 sites were screened initially (Table S1); the 14 sites shown (selected to include representatives of varying editing efficiencies, as measured by TIDE) were then re-analyzed in triplicate. An Nme1Cas9 target site (with an N4GATT PAM) was used as a negative control.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) Nme2Cas9 genome editing of endogenous human sites in HEK293T cells following transient transfection of Nme2Cas9- and sgRNA-expressing plasmids. 40 sites were screened initially (Table S1); the 14 sites shown (selected to include representatives of varying editing efficiencies, as measured by TIDE) were then re-analyzed in triplicate. An Nme1Cas9 target site (with an N4GATT PAM) was used as a negative control.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: Transfection, Expressing, Negative Control

(A) In vitro cleavage assay of Nme1Cas9 and Nme2Cas9 in the presence of five previously characterized anti-CRISPR proteins (10:1 ratio of Acr:Cas9). Top: Nme1Cas9 efficiently cleaves its target in the absence of an Acr or in the presence of a negative control Acr (AcrE2). All five type II-C Acr families inhibited Nme1Cas9, as expected. Bottom: Nme2Cas9 inhibition mirrors that of Nme1Cas9, except for the lack of inhibition by AcrIIC5Smu.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) In vitro cleavage assay of Nme1Cas9 and Nme2Cas9 in the presence of five previously characterized anti-CRISPR proteins (10:1 ratio of Acr:Cas9). Top: Nme1Cas9 efficiently cleaves its target in the absence of an Acr or in the presence of a negative control Acr (AcrE2). All five type II-C Acr families inhibited Nme1Cas9, as expected. Bottom: Nme2Cas9 inhibition mirrors that of Nme1Cas9, except for the lack of inhibition by AcrIIC5Smu.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: In Vitro, Cleavage Assay, CRISPR, Negative Control, Inhibition

(A) Nme2Cas9 and SpyCas9 efficiencies vary based on the locus and target site. Dual sites (flanked by NGGNCC sequences) throughout the genome were selected for direct comparisons of editing by the two orthologs in HEK293T cells. Box-and-whisker plots indicate editing efficiencies at 28 dual sites by Nme2Cas9 and SpyCas9 (left). The sites that showed no editing were excluded from the analysis. Relative efficiencies of Nme2Cas9 and SpyCas9 show that Nme2Cas9 is less efficient than SpyCas9 (right), on average. Editing efficiencies by both Cas9 orthologs at all 28 sites were included in the analysis of relative efficiencies in the right panel.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) Nme2Cas9 and SpyCas9 efficiencies vary based on the locus and target site. Dual sites (flanked by NGGNCC sequences) throughout the genome were selected for direct comparisons of editing by the two orthologs in HEK293T cells. Box-and-whisker plots indicate editing efficiencies at 28 dual sites by Nme2Cas9 and SpyCas9 (left). The sites that showed no editing were excluded from the analysis. Relative efficiencies of Nme2Cas9 and SpyCas9 show that Nme2Cas9 is less efficient than SpyCas9 (right), on average. Editing efficiencies by both Cas9 orthologs at all 28 sites were included in the analysis of relative efficiencies in the right panel.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: Whisker Assay

(A) Workflow for delivery of AAV8.sgRNA.Nme2Cas9 to reduce serum cholesterol levels in mice by targeting Pcsk9. Top: schematic of the all-in-one AAV vector expressing Nme2Cas9 and the sgRNA. BGH, bovine growth hormone poly(A) site; HA, epitope tag; NLS, nuclear localization sequence; h, human-codon-optimized. Bottom: Timeline for AAV8.sgRNA.Nme2Cas9 tail-vein injections and analyses.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) Workflow for delivery of AAV8.sgRNA.Nme2Cas9 to reduce serum cholesterol levels in mice by targeting Pcsk9. Top: schematic of the all-in-one AAV vector expressing Nme2Cas9 and the sgRNA. BGH, bovine growth hormone poly(A) site; HA, epitope tag; NLS, nuclear localization sequence; h, human-codon-optimized. Bottom: Timeline for AAV8.sgRNA.Nme2Cas9 tail-vein injections and analyses.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: Plasmid Preparation, Expressing, Sequencing

(A) Workflow for single-AAV Nme2Cas9 editing ex vivo to generate albino C57BL/6NJ mice by targeting the Tyr gene. Zygotes are treated with AAV6.Nme2Cas9:sg Tyr and then transferred to the oviduct of pseudo-pregnant recipients.

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: (A) Workflow for single-AAV Nme2Cas9 editing ex vivo to generate albino C57BL/6NJ mice by targeting the Tyr gene. Zygotes are treated with AAV6.Nme2Cas9:sg Tyr and then transferred to the oviduct of pseudo-pregnant recipients.

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: Ex Vivo

KEY RESOURCES TABLE

Journal: Molecular cell

Article Title: A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing

doi: 10.1016/j.molcel.2018.12.003

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Codon-optimized Nme2Cas9 , Genscript , N/A.

Techniques: Virus, Recombinant, Transfection, Cloning, Protease Inhibitor, Software